A Phase 1/2 interventional study of TQB3909 tablet in Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma, sponsored by Chia Tai Tianqing Pharmaceutical Group Co., Ltd.. Recruiting at 25 sites in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2023-10-23.
Sponsored by Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (part of Sino Biopharmaceutical Limited) · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 108 studies in Leukemia, Lymphocytic, Chronic, B-Cell with a site in China — 39 open to participants now, 60 under way, 19 of them phase 3. Leukemia, Lymphocytic, Chronic, B-Cell · China.
Among the 108 studies in Leukemia, Lymphocytic, Chronic, B-Cell with a site in China, this one is the 40th largest by planned enrollment of the 105 interventional ones that give a count, is one of 9 that started in 2023, is one of 27 in phase 1/2, reaches primary completion later than 17 of the 59 other live ones, and was the 81st registered.
2,036 studies on the registry are indexed under Leukemia, Lymphocytic, Chronic, B-Cell; 236 are open to participants now.
Browse Leukemia, Lymphocytic, Chronic, B-Cell studies →39 of the 108 studies in Leukemia, Lymphocytic, Chronic, B-Cell with a site in China are open now. Recruiting first, the newest first:
Guangzhou Lupeng Pharmaceutical Company LTD. · Sites in China
Ages 18+
Guangzhou Lupeng Pharmaceutical Company LTD. · Sites in China
Ages 18+
Eli Lilly and Company · Sites in China, United States, Australia and 14 more countries
Ages 18+
BeOne Medicines · Sites in China, United States, Australia and 14 more countries
Ages 18+
The First Affiliated Hospital with Nanjing Medical University · Sites in China
Ages 18–80
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 187 Leukemia, Lymphocytic, Chronic, B-Cell studies recruiting now, 150 (80%) set no upper age limit and 15 (8%) stop at 75 or younger; 17 take children under 18; 12 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
108 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 54 · Phase 2 48 · Phase 3 25 · Phase 4 1
First in 2010; this study’s year is marked. 9 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 107 is above the median of 39 across 1,603 interventional studies indexed under Leukemia, Lymphocytic, Chronic, B-Cell.
Median enrollment 89 across the 105 interventional studies, 160 across the 3 observational. Of the 17 that completed or were terminated, 7 (41%) have results posted.
This tab as a report to print or save as PDF → With an account.
72 of 108 have an industry lead sponsor. The 10 most frequent:
This study is registered under Chia Tai Tianqing Pharmaceutical Group Co., Ltd., one of the names counted as Sino Biopharmaceutical Limited. Under that name alone:
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. is the lead sponsor of 320 studies on the registry; 76 are open to participants now.
Sino Biopharmaceutical Limited has 2 studies filed under Leukemia, Lymphocytic, Chronic, B-Cell — fewer than ten, so there is no comparison to draw.
12 of the studies in Leukemia, Lymphocytic, Chronic, B-Cell with a site in China that are under way reach primary completion within a year, 4 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT01804686Phase 3Janssen Research & Development, LLCA Long-term Extension Study of PCI-32765 (Ibrutinib) | 2026-12-31 |
| NCT03836261Phase 3Acerta Pharma BVStudy of Acalabrutinib (ACP-196) in Combination With Venetoclax (ABT-199), With and Without Obinutuzumab (GA101) Versus Chemoimmunotherapy for Previously Untreated CLL | 2027-04-30 |
| NCT05624554Phase 3Merck Sharp & Dohme LLCA Study of Nemtabrutinib vs Chemoimmunotherapy for Participants With Previously Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Without TP53 Aberrations (MK-1026-008, BELLWAVE-008) | 2027-05-19 |
| NCT05254743Phase 3Loxo Oncology, Inc.A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) | 2027-10 |
| NCT06637501BeOne MedicinesA Study to Investigate Sonrotoclax Combined With Zanubrutinib Versus Zanubrutinib Alone in Participants With Previously Untreated Chronic Lymphocytic Leukemia | 2026-11 |
Add all 12 to your calendar (.ics) → With an account.
Among the 108 studies in Leukemia, Lymphocytic, Chronic, B-Cell with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a phase Ib/II clinical trial to evaluate the safety and efficacy of TQB3909 tablets in patients with recurrent or refractory CLL/SLL.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Complicated diseases and medical history:
Tumor-related symptoms and treatment:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CTCAE grade
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
PD-1, PD-L1 and checkpoint inhibitors
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Oral administration, 400mg or 600 mg, once a day, and 28 days is a treatment cycle. Continue medication until the disease progresses or intolerant toxicity appears.
Drug: TQB3909 tablet
TQB3909 is an inhibitor targeting at B-cell lymphoma (BCL)-2 protein.
Incidence of adverse events (AE)
Incidence of AE evaluated by CTCAE 5.0 (Common Terminology Criteria for Adverse Events 5.0).
Time frame: Up to 34 months.
Severity of adverse events (AE)
Severity of AE evaluated by CTCAE 5.0 (Common Terminology Criteria for Adverse Events 5.0).
Time frame: Up to 34 months.
Incidence of serious adverse events (SAE)
Incidence of SAE evaluated by CTCAE 5.0 (Common Terminology Criteria for Adverse Events 5.0).
Time frame: Up to 34 months.
Severity of serious adverse events (SAE)
Severity of SAE evaluated by CTCAE 5.0 (Common Terminology Criteria for Adverse Events 5.0).
Time frame: Up to 34 months.
Incidence of abnormal laboratory examination indexes.
Incidence of abnormal laboratory examination indexes evaluated by CTCAE 5.0 (Common Terminology Criteria for Adverse Events 5.0).
Time frame: Up to 34 months.
Severity of abnormal laboratory examination indexes.
Severity of abnormal laboratory examination indexes evaluated by CTCAE 5.0 (Common Terminology Criteria for Adverse Events 5.0).
Time frame: Up to 34 months.
Recommended phase II dose (RP2D)
To determine the recommended phase II dose of TQB3909 tablets in the treatment of recurrent or refractory CLL/SLL.
Time frame: Up to 18 months
Objective remission rate (ORR) determined by Independent Review Committee (IRC)
Determine the objective remission rate (ORR) based on the evaluation results of the Independent Review Committee (IRC), defined as the proportion of subjects whose best remission is complete remission (CR) and partial remission (PR).
Time frame: Up to 34 months
Objective remission rate (ORR) determined by the investigators' evaluation.
The objective remission rate (ORR) was determined by the results of the investigator s' evaluation, defined as the proportion of subjects whose best remission is complete remission (CR) and partial remission (PR).
Time frame: Up to 34 months
Duration of remission (DOR)
For all subjects whose best response was PR, CR,, the time from the date of first achieving PR, CR to the date of first definite disease progression or death from any cause (whichever occurs first).
Time frame: Up to 34 months
Time to disease progression (TTP)
Refers to the time from the first medication to the objective progress of the disease.
Time frame: Up to 34 months
Time to remission (TTR)
Time from the beginning of treatment to the first recording of remission (PR or better remission), only the remission population was analyzed.
Time frame: Up to 34 months
Progression-free survival (PFS)
The time from the first medication to the objective progression of the disease or death caused from any cause (whichever comes first).
Time frame: Up to 34 months
Overall survival (OS)
Time from first dose of study drug to date of death from any cause.
Time frame: Up to 34 months
Time to reach maximum concentration (Tmax)
Time to reach maximum plasma concentration after single and multiple dosing of TQB3909 tablets.
Time frame: Within 120 hours after administration
Maximum plasma drug concentration (Cmax)
Cmax is the maximum plasma concentration of TQB3909.
Time frame: Within 120 hours after administration
Area under the plasma concentration-time curve (AUC0-t)
To characterize the pharmacokinetics of TQB3909 by assessment of area under the plasma concentration time curve.
Time frame: Within 120 hours after administration
Plasma elimination half-life (t1/2)
t1/2 is time it takes for the blood concentration of TQB3909 to drop by half.
Time frame: Within 120 hours after administration
Undetectable measurable residual disease (U-MRD) ratio of peripheral blood and/or bone marrow.
Refers to the undetected residual lesions. Peripheral blood and/or bone marrow are used to detect less than 1 CLL cell (less than 10-4) in 10000 white blood cells by flow cytometry.
Time frame: Up to 34 months
Correlation between potential biomarkers and TQB3909 tablets.
Correlation of potential biomarkers with TQB3909 tablets: such as BTK and PLCG2 mutation status and allele frequency.
Time frame: Up to 34 months
Started Oct 2023 (actual). Primary completion is estimated for Dec 2025, 26 months after the start.
Of 50 industry-sponsored phase 1/2 interventional studies under Leukemia, Lymphocytic, Chronic, B-Cell, half reached primary completion within 80 months of starting (the median), counting those still running; a quarter within 51 and three quarters within 104. This study's planned 26 months is below that.
Counting every sponsor, half of 90 studies reached it within 78 months; a quarter within 51 and three quarters within 103.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Bcl-2 Inhibitor TQB3909
Leukemia, Lymphocytic, Chronic, B-Cell →
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. →